

## Jynarque<sup>®</sup> (tolvaptan) – First-time generic

- On May 13, 2025, [Lupin launched](#) an [AB-rated](#) generic version of Otsuka's [Jynarque \(tolvaptan\)](#) tablets.
  - Lupin was granted 180-days of generic exclusivity for its generic Jynarque.
- Jynarque is approved to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease.
- Jynarque carries a boxed warning for risk of serious liver injury.
- According to IQVIA, Jynarque had estimated annual U.S. sales of \$1.5 billion ending December 2024.